Browsing by Author "Özçelik M."

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Predictive and prognostic factors in ovarian and uterine carcinosarcomas
    (AVES Ibrahim Kara, 2016) Cicin İ.; Özatlı T.; Türkmen E.; Özturk T.; Özçelik M.; Çabuk D.; Gökdurnalı A.; Balvan Ö.; Yıldız Y.; Şeker M.; Özdemir N.; Yapar B.; Tanrıverdi Ö.; Günaydin Y.; Menekşe S.; Öksüzoğlu B.; Aksoy A.; Erdogan B.; Hacıoglu M.B.; Arpaci E.; Sevinç A.
    Background: Prognostic factors and the standard treatment approach for gynaecological carcinosarcomas have not yet been clearly defined. Although carcinosarcomas are more aggressive than pure epithelial tumours, they are treated similarly. Serous/clear cell and endometrioid components may be predictive factors for the efficacy of adjuvant chemotherapy (CT) or radiotherapy (RT) or RT in patients with uterine and ovarian carcinosarcomas. Heterologous carcinosarcomas may benefit more from adjuvant CT. Aims: We aimed to define the prognostic and predictive factors associated with treatment options in ovarian (OCS) and uterine carcinosarcoma (UCS). Study Design: Retrospective cross-sectional study Methods: We retrospectively reviewed the medical records of patients with ovarian and uterine carcinosarcoma from 2000 to 2013, and 127 women were includ ed in this study (24 ovarian and 103 uterine). Patients admitted to seventeen oncology centres in Turkey between 2000 and December 2013 with a histologically proven diagnosis of uterine carcinosarcoma with FIGO 2009 stage I-III and patients with sufficient data obtained from well-kept medical records were included in this study. Stage IV tumours were excluded. The patient records were retrospectively reviewed. Data from 104 patients were evaluated for this study. Results: Age (≥70 years) was a poor prognostic factor for UCS (p=0.036). Pelvic±para aortic lymph node dissection did not affect overall survival (OS) (p=0.35). Macroscopic residual disease was related with OS (p<0.01). The median OS was significantly longer in stage I-II patients than stage III patients (p=0.03). Adjuvant treatment improved OS (p=0.013). Adjuvant radiotherapy tended to increase the median OS (p=0.075). However, this tendency was observed in UCS (p=0.08) rather than OCS (p=0.6).Adjuvant chemotherapy had no effect on OS (p=0.15).Adjuvant radiotherapy significantly prolonged the median OS in patients with endometrioid component (p=0.034). A serous/clear cell component was a negative prognostic factor (p=0.035). Patients with serous/clear cell histology for whom adjuvant chemotherapy was applied had significantly longer OS (p=0.019), and there was no beneficial effect of adjuvant radiotherapy (p=0.4). Adjuvant chemotherapy was effective in heterologous tumours (p=0.026). In multivariate analysis, the stage and chemotherapy were prognostic factors for all patients. Age was an independent prognostic factor for UCS. However, serous/clear cell histology and radiotherapy tended to be significant prognostic factors. Conclusion: The primary location, the histological type of sarcomatous and the epithelial component may be predictive factors for the efficacy of chemotherapy or radiotherapy in UCS and OCS. © Trakya University Faculty of Medicine.
  • No Thumbnail Available
    Item
    Extraction, characterization, and rheology of Opuntia ficus indica cladode polysaccharides
    (John Wiley and Sons Inc, 2022) Sevgi A.; Özçelik M.; Yılmaz T.
    In this study, hot water extraction was applied to obtain water-soluble pectin of Opuntia ficus indica (OFI) cladode. The yield was found 0.18–0.06% in fresh-weight with the degree of esterification at 48 ± 1.25% expressing that extracted polysaccharide has low-methoxyl (LM) pectin features. Some properties of OFI cladode pectin and commercial LM pectin were investigated. Infrared spectrums of the samples were found mostly similar by having major pectin constituents. 0.25, 0.5, 1, 2 and 3% w/v solutions were prepared for rheological properties at 25, 30, 35 and 40°C. Solutions prepared both using commercial pectin (CP) and OCP represented Newtonian behavior at applied shear rate region. More than 1% w/v concentration, CP showed higher thickening property compared to OCP solutions at various temperatures where CP samples were heavier compared to OCP. The activation energy of OCP solutions was higher than CP meaning that CP had stronger interaction between molecules by representing better stability. Novelty impact statement: Opuntia ficus indica (OFI) is well known as the fruit part, however, the cladode part has a great potential for food use as a polysaccharide source. Cladode is rich in water-soluble pectic polysaccharides and there is no commercial cladode pectin available on the market. OFI cladode can be used as a cheap source of low-methoxyl pectin with some modifications due to the application area. © 2021 Wiley Periodicals LLC.
  • No Thumbnail Available
    Item
    The Effectiveness of Adjuvant PD-1 Inhibitors in Patients with Surgically Resected Stage III/IV Acral Melanoma
    (Lippincott Williams and Wilkins, 2024) Arak H.; Erkiliç S.; Yaslikaya Ş.; Eylemer Mocan E.; Aktaş G.; Özdemir M.; Semiz H.S.; Kiliçkap S.; Özalp F.R.; Sever Ö.N.; Akdaǧ G.; Aǧaoǧlu A.B.; Özçelik M.; Sari M.; Arcagök M.; Anik H.; Yayla Ş.B.; Sever N.; Açar F.P.; Bayrakçi İ.; Turhal S.; Ayhan M.; Kuş T.
    Our aim was to assess the efficacy of adjuvant programmed cell death protein-1 (PD-1) inhibitors and compare the other adjuvant treatments in patients with surgically resected stage III or IV acral melanoma. This study is a multicenter, retrospective analysis. We included 114 patients with stage III or IV acral malignant melanoma who underwent surgery within the past 10 years. We analyzed the effect of adjuvant programmed cell death protein-1 inhibitors on disease-free survival (DFS). The mean follow-up was 40 months, during which 69 (59.5%) patients experienced recurrence. Among the participants, 64 (56.1%) received systemic adjuvant therapy. Specifically, 48.4% received anti-PD-1 therapy, 29.7% received interferon, 14.1% received tezozolomide, and 7.8% received B-Raf proto-oncogene/mitogen-activated protein kinase inhibitors. Patients who received adjuvant therapy had a median DFS of 24 (10.9-37.2) months, whereas those who did not receive adjuvant therapy had a median DFS of 15 (9.8-20.2) months. Multivariate analysis for DFS revealed that the receipt of adjuvant therapy and lymph node metastasis stage were independent significant parameters (P = 0.021, P = 0.018, respectively). No statistically significant difference was observed for DFS between programmed cell death protein-1 inhibitor treatment and other adjuvant treatments. Regarding overall survival (OS), patients who received adjuvant treatment had a median OS of 71 (30.4-111.7) months, whereas those who did not receive adjuvant treatment had a median OS of 38 (16.7-59.3; P = 0.023) months. In addition, there were no significant differences in OS observed between various adjuvant treatment agents (P = 0.122). In our study, we have shown that adjuvant therapy had a positive effect on both DFS and OS in patients with stages III-IV acral melanoma who underwent curative intent surgery. Notably, we found no significant differences between anti-PD-1 therapy and other adjuvant therapies. © 2024 Lippincott Williams and Wilkins. All rights reserved.